Research Briefing
Published: 25 June 2024
Nature Biotechnology
(2024)Cite this article
Subjects
We use a CRISPR screening platform based on adeno-associated virus and the Sleeping Beauty transposon (AAV-SB-CRISPR) to perform in vivo CRISPR screens in primary natural killer (NK) cells across four different tumor models, and identify calcium homeostasis modulator family member 2 (CALHM2) as an NK cellular checkpoint protein.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: AAV-SB-CRISPR screens and single-cell RNA sequencing of tumor-infiltrating NK cells jointly identify CALHM2 as an NK cellular checkpoint.
References
Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat. Med. 30, 772–784 (2024). A recent clinical trial demonstrating the robust efficacy and superior safety of CAR-NK.
Vivier, E. et al. Natural killer cell therapies. Nature 626, 727–736 (2024). Comprehensive review discussing the current status of NK therapy.
Dong, M. B. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell 178, 1189–1204 (2019). This paper reports an early in vivo CRISPR screens in primary T cells.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ye, L. et al. In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat. Biotechnol. 37, 1302–1313 (2019). This paper demonstrates the application of an AAV-SB-CRISPR system in T cells.
Article
CAS
PubMed
PubMed Central
Google Scholar
Download references
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Peng, L. et al. In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02282-4 (2024).
Rights and permissions About this article
Cite this article
CRISPR screens of tumor-infiltrating NK cells identify genetic checkpoints for CAR-NK therapy.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02319-8
Download citation
Published: 25 June 2024
DOI : https://doi.org/10.1038/s41587-024-02319-8
Information contained on this page is provided by an independent third-party content provider. This website makes no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact editor @americanfork.business
